Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 64

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 64
---
2024 ESPP as of June 30, 2025.

On March 4, 2025, the Company’s Board of Directors granted an
aggregate of 20,313 stock options under the 2024 Plan, to board members, exercisable on the date of grant at $28.60 per share with a ten-year
term and vest over a requisite service period, which is usually the vesting period, and upon the completion of certain performance-based
vesting terms. These options were valued at $488,720 on the grant date using a Black Scholes option pricing model using the assumptions
summarized below. The Company recorded the fair value of the unvested stock options, in the amount of $488,720 as deferred compensation
on the grant date, which is being amortized over the vesting period or upon the completion of certain performance-based vesting terms.

On May 30, 2025, the Company’s Board of Directors granted an
aggregate of 50,591 stock options under the 2024 Plan, to executive officers, board members, employees, and consultants, exercisable on
the date of grant at $8.91 per share with a ten-year term and vest over a requisite service period, which is usually the vesting period,
or upon the completion of certain performance-based vesting terms. These options were valued at $351,862 on the grant date using a Black
Scholes option pricing model using the assumptions summarized below. The Company recorded the fair value of the unvested stock options,
in the amount of $351,862 as deferred compensation on the grant date, which is being amortized over the vesting period or upon the completion
of certain performance-based vesting terms.

<div align='center'>28</div>

Stock option activity under the 2024 Plan for the six months ended June 30, 2025 was as follows:

|                                         |     | Outstanding 
 Shares      |        |     | Weighted  
 Average   
 Exercise  
 Price Per 
 Share     |        |     | Weighted    
 Average     
 Remaining   
 Contractual 
 Life        
 (in         
 Years)      |      |
|:----------------------------------------|:----|:------------|-------:|:----|:----------|-------:|:----|:------------|-----:|
| Balance, December 31, 2024 (Successor)  |     |             |  3,247 |     | $         | 200.00 |